Bristol-Myers Squibb (BMY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Bristol-Myers Squibb

NYSE•Healthcare•Drug Manufacturers - General

$61.71-1.31(-0.02%)After hours

Market Cap

$127.11B

P/E

13.8x

P/S

2.5x

P/B

5.4x

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

How this company scores

GoodMetricSide Score: 72/100

Strongest: Profitability (25/25); weakest: Balance Sheet & Red Flags (14/25).

Profitability25/25

Growth17/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality16/25

Strengths

Strong marginsHigh ROERising earningsCash-backed earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 13.8x5y range 12.9x – 25.3x

Currently near its 16-quarter median.

P/S · 2.5x5y range 1.8x – 3.5x

Currently near its 20-quarter median.

P/B · 5.4x5y range 3.5x – 7.1x

Currently near its 20-quarter median.

Price & Volume

Market Cap $127.11B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $50.03B
Q. Revenue: $13.07B
TTM EBITDA: $19.55B
TTM Op. Income: $16.76B
Q. Op. Income: $4.86B
TTM Net Income: $9.24B
Q. Net Income: $2.16B
EPS: $1.06
Shares Out.: $2.04B

$50.03B in TTM revenue grew 4.2% YoY, reaching $13.07B last quarter. TTM EBITDA of $19.55B and TTM operating income of $16.76B show growth is flowing through to the bottom line. TTM net income of $9.24B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 68.3%
EBITDA Margin: 42.0%
Op. Margin: 37.2%
Net Margin: 16.5%

Op. margin of 37.2% is up 0.6% YoY — cost efficiency is improving. Net margin at 16.5% and gross margin of 68.3% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 13.8x
P/S Ratio: 2.5x
P/B Ratio: 5.4x

At 13.8x P/E, the stock trades below typical market levels. P/S of 2.5x and P/B of 5.4x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 8% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $88.77B
Cash: $9.57B
Long-Term Debt: $41.85B
Book Value: $23.40B
D/E Ratio: 1.8
Debt/EBITDA: 7.6

With $88.77B in assets and $41.85B in long-term debt, D/E is 1.8and book value is $23.40B — moderate leverage. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $4.18B
TTM Free Cash Flow: $9.29B
FCF Margin: 18.6%
FCF / Net Income: 1.0

TTM FCF of $9.29B on $4.18B in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.